Hervé Duchesne de Lamotte, chief financial officer, ExonHit Therapeutics

ExonHit Therapeutics appoints Hervé Duchesne de Lamotte chief financial officer.

The Paris-based company develops innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications.

"We are very pleased to welcome Hervé Duchesne de Lamotte to the company. He will provide ExonHit with the benefit of his strong financial experience in the healthcare field and his international skills in strategy and consulting - all of which are significant assets for the pursuit of our corporate objectives," stated Loïc Maurel, President of ExonHit Therapeutics' Management Board.

Hervé Duchesne de Lamotte has over 25 years of international financial experience, including 10 years within the biotechnology industry.

After having held a variety of project management positions in consultancy firms in France and the US between 1981 and 1989, Hervé Duchesne de Lamotte took up a senior position at a Paris-based asset management firm.

In 1998, he moved into pharma and biotechnology by joining the IDM group, where he served as CFO for 10 years in France, Canada, and the US.

He was subsequently appointed Chief Operating Officer, France, at IDM Paris from 2006 to 2008. Prior to joining ExonHit Therapeutics, Hervé Duchesne de Lamotte managed Cirrus Finance Management, a consultancy firm specializing in business and organizational strategies.

He joins ExonHit Therapeutics following the recently announced successful completion of phase IIa clinical trials for EHT 0202 (its lead drug candidate in Alzheimer's disease) and ongoing discussions with potential partners for further development and commercialisation of the drug.